Naomi Walsh

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Jojanneke Stoof · 4 shared papers, 2021–2026 · strength 1.02
   • Paper Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma. DOI 10.1111/jcmm.70816↗
   • Paper Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer. DOI 10.1016/j.biopha.2026.119273↗
   • Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004↗
2. Shannon R. Nelson · 5 shared papers, 2020–2025 · strength 0.80
   • Paper Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. DOI 10.3390/cancers12051233↗
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
3. Greta Bagnolini · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
4. Marinella Roberti · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
5. Stefania Girotto · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
6. Andrea Cavalli · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
7. Samuel Harry Myers · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
8. Maeve Aine Lowery · 2 shared papers, 2021–2025 · strength 0.47
   • Paper Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma. DOI 10.1111/jcmm.70816↗
   • Paper DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. DOI 10.3389/fcell.2021.749490↗
9. Mirco Masi · 2 shared papers, 2024–2025 · strength 0.35
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
10. Sara Noorani · 1 shared paper, 2026 · strength 0.30
    • Paper Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer. DOI 10.1016/j.biopha.2026.119273↗
11. Paula Meleady · 1 shared paper, 2026 · strength 0.30
    • Paper Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer. DOI 10.1016/j.biopha.2026.119273↗
12. Annemarie Larkin · 3 shared papers, 2013–2020 · strength 0.25
    • Paper Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line org… DOI 10.1038/s41598-020-59368-7↗
    • Paper Genomic Profiling and Functional Analysis of let-7c miRNA-mRNA Interactions Identify SOX13 to Be Involved in Invasion a… DOI 10.1155/2020/2951921↗
    • Paper EGFR and HER2 inhibition in pancreatic cancer. DOI 10.1007/s10637-012-9891-x↗
13. Yanxi Lu · 1 shared paper, 2025 · strength 0.25
    • Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004↗
14. Jelena Grahovac · 1 shared paper, 2025 · strength 0.25
    • Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004↗
15. Robert Grützmann · 1 shared paper, 2025 · strength 0.25
    • Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004↗
16. Tianhui Chen · 1 shared paper, 2025 · strength 0.25
    • Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004↗
17. Christian P. Pilarsky · 1 shared paper, 2025 · strength 0.25
    • Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004↗
18. Maarten F. Bijlsma · 1 shared paper, 2025 · strength 0.25
    • Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004↗
19. Sandra Roche · 2 shared papers, 2020 · strength 0.21
    • Paper Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line org… DOI 10.1038/s41598-020-59368-7↗
    • Paper Genomic Profiling and Functional Analysis of let-7c miRNA-mRNA Interactions Identify SOX13 to Be Involved in Invasion a… DOI 10.1155/2020/2951921↗
20. Fiona O’Neill · 2 shared papers, 2020 · strength 0.21
    • Paper Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line org… DOI 10.1038/s41598-020-59368-7↗
    • Paper Genomic Profiling and Functional Analysis of let-7c miRNA-mRNA Interactions Identify SOX13 to Be Involved in Invasion a… DOI 10.1155/2020/2951921↗
21. Benoît Immordino · 1 shared paper, 2024 · strength 0.19
    • Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
22. Macarena Perán · 1 shared paper, 2024 · strength 0.19
    • Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
23. Manoj Amrutkar · 1 shared paper, 2024 · strength 0.19
    • Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
24. Cristina P. R. Xavier · 1 shared paper, 2024 · strength 0.19
    • Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
25. Rita Rebelo · 1 shared paper, 2024 · strength 0.19
    • Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.